Piper Sandler raised the firm’s price target on Edwards Lifesciences (EW) to $83 from $80 and keeps an Overweight rating on the shares. The firm believes it is a question of when — not if — the TAVR NCD is re-opened, but admittedly timing is difficult to predict. Piper would argue that the recent FDA approval for asymptomatic AS is about as good of an excuse as any to revisit the NCD document. The firm thinks coverage of asymptomatic AS patients under the NCD would be a tailwind to adoption as it would streamline reimbursement for this patient segment. Another reason a reconsideration of the NCD is important is because it would give CMS the chance to re-evaluate and potentially remove the volume requirements to start a new TAVR program. Piper believes there’s a good shot that this gets addressed once the NCD re-opens. More centers should help alleviate some lingering capacity constraints and it thinks translate into more TAVR volumes.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences Expands Employee Stock Purchase Plans
- Balanced Outlook on Edwards Lifesciences: Navigating FDA Approval and Capacity Constraints
- Cadence, Apple, Edwards, Mondelez, American Water: Trending by Analysts
- Edwards Lifesciences Reports Robust Q1 2025 Growth
- Cautious Outlook on Edwards Lifesciences Amid Growth Potential and Market Challenges
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue